Oral Administration of Live and Dead Cells of Lactobacillus sakei proBio65 Alleviated Atopic Dermatitis in Children and Adolescents: a Randomized, Double-Blind, and Placebo-Controlled Study
Several studies suggest that probiotics might be useful in the management of atopic dermatitis (AD). However, the efficacy and comparison between both the administration of viable and non-viable probiotics on alleviation of AD is not well studied. Therefore, the purpose of this study was to evaluate...
Gespeichert in:
| Veröffentlicht in: | Probiotics and antimicrobial proteins 2021-04, Vol.13 (2), p.315-326 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 326 |
|---|---|
| container_issue | 2 |
| container_start_page | 315 |
| container_title | Probiotics and antimicrobial proteins |
| container_volume | 13 |
| creator | Rather, Irfan A. Kim, Byung-Chun Lew, Lee-Ching Cha, Seong-Kwan Lee, Jong Hwan Nam, Gyeong-Jun Majumder, Rajib Lim, Jeongheui Lim, Seul-Ki Seo, Young-Joon Park, Yong-Ha |
| description | Several studies suggest that probiotics might be useful in the management of atopic dermatitis (AD). However, the efficacy and comparison between both the administration of viable and non-viable probiotics on alleviation of AD is not well studied. Therefore, the purpose of this study was to evaluate the effect of
L. sakei
proBio65 live and dead cells when administered (1 × 10
10
cells/day) for 12 weeks to children and adolescents (aged 3 to 18) with atopic dermatitis. In this randomized double-blind, placebo-controlled study, ninety patients were recruited and randomly allocated to either the
L. sakei
proBio65 live cells,
L. sakei
proBio65 dead cells, or placebo groups. Assessment of efficacy was based on the change in SCORing Atopic Dermatitis (SCORAD) score, Investigators Global Assessment (IGA) score, serum inflammatory markers such as the serum eosinophil (count), IgE, eosinophil cationic protein (ECP), CCL17 (thymus and activation-regulated chemokine [TARC]), and CCL27 (cutaneous T cell–attracting chemokine [CTACK]), and changes in skin condition (moisture and sebum) at baseline, week 6 and week 12. The SCORAD total score decreased in the live cells (
p =
0.0015) and dead cell group (
p =
0.0017) from the baseline after 12 weeks, whereas there were no significant changes in the placebo group when compared with baseline. The skin sebum content increased in both the live cell (
p <
0.0001) and the dead cell group (
p <
0.0001), suggesting potential improvements in skin barrier functions. Current data suggested a positive improvement in alleviation of AD symptoms upon oral administration of
L. sakei
proBio65 in both viable and non-viable forms. |
| doi_str_mv | 10.1007/s12602-020-09654-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2444378421</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2444378421</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2907-7c1ec7420c24b65bc970f00b820b15d0eeffa7c6265bcb0a27838cbd1141f0c33</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhSMEoqXwAiyQJTYsCIydxE7YpWn5ka5UxM86cuwJuDj2xXYqlXfj3ep7bykSC1a2Z75zZqxTFE8pvKIA4nWkjAMrgUEJHW_qUtwrjmnLRUkrWt-_uwM_Kh7FeAnAecXgYXFUsa7ugNLj4vdFkJb0ejHOxBRkMt4RP5ONuUIinSZnKDUZ0Nq4L0uV_CSVsXaNJMofaMg2-FPjeUN6a_HKyISa9MlvjcrisGTLZCIxjgzfjdUB3d63195iVOhSfEMk-ZRrfjG_UL8kZ36dLJan1rj82sEfrVQ4-XLwLgWfx2jyOa36-nHxYJY24pPb86T4-vb8y_C-3Fy8-zD0m1KxDkQpFEUlagaK1RNvJtUJmAGmlsFEGw2I8yyF4mzXm0Ay0VatmjSlNZ1BVdVJ8eLgm__6c8WYxsXk3a2VDv0aR1bXdSXamtGMPv8HvfRrcHm7kTXQdcDbbmfIDpQKPsaA87gNZpHheqQw7sIdD-GOOdxxH-4osujZrfU6LajvJH_SzEB1AGJuuW8Y_s7-j-0NVgmwgw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2509906893</pqid></control><display><type>article</type><title>Oral Administration of Live and Dead Cells of Lactobacillus sakei proBio65 Alleviated Atopic Dermatitis in Children and Adolescents: a Randomized, Double-Blind, and Placebo-Controlled Study</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Rather, Irfan A. ; Kim, Byung-Chun ; Lew, Lee-Ching ; Cha, Seong-Kwan ; Lee, Jong Hwan ; Nam, Gyeong-Jun ; Majumder, Rajib ; Lim, Jeongheui ; Lim, Seul-Ki ; Seo, Young-Joon ; Park, Yong-Ha</creator><creatorcontrib>Rather, Irfan A. ; Kim, Byung-Chun ; Lew, Lee-Ching ; Cha, Seong-Kwan ; Lee, Jong Hwan ; Nam, Gyeong-Jun ; Majumder, Rajib ; Lim, Jeongheui ; Lim, Seul-Ki ; Seo, Young-Joon ; Park, Yong-Ha</creatorcontrib><description>Several studies suggest that probiotics might be useful in the management of atopic dermatitis (AD). However, the efficacy and comparison between both the administration of viable and non-viable probiotics on alleviation of AD is not well studied. Therefore, the purpose of this study was to evaluate the effect of
L. sakei
proBio65 live and dead cells when administered (1 × 10
10
cells/day) for 12 weeks to children and adolescents (aged 3 to 18) with atopic dermatitis. In this randomized double-blind, placebo-controlled study, ninety patients were recruited and randomly allocated to either the
L. sakei
proBio65 live cells,
L. sakei
proBio65 dead cells, or placebo groups. Assessment of efficacy was based on the change in SCORing Atopic Dermatitis (SCORAD) score, Investigators Global Assessment (IGA) score, serum inflammatory markers such as the serum eosinophil (count), IgE, eosinophil cationic protein (ECP), CCL17 (thymus and activation-regulated chemokine [TARC]), and CCL27 (cutaneous T cell–attracting chemokine [CTACK]), and changes in skin condition (moisture and sebum) at baseline, week 6 and week 12. The SCORAD total score decreased in the live cells (
p =
0.0015) and dead cell group (
p =
0.0017) from the baseline after 12 weeks, whereas there were no significant changes in the placebo group when compared with baseline. The skin sebum content increased in both the live cell (
p <
0.0001) and the dead cell group (
p <
0.0001), suggesting potential improvements in skin barrier functions. Current data suggested a positive improvement in alleviation of AD symptoms upon oral administration of
L. sakei
proBio65 in both viable and non-viable forms.</description><identifier>ISSN: 1867-1306</identifier><identifier>EISSN: 1867-1314</identifier><identifier>DOI: 10.1007/s12602-020-09654-7</identifier><identifier>PMID: 32949011</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Administration, Oral ; Adolescent ; Adolescents ; Applied Microbiology ; Atopic dermatitis ; CCL17 protein ; Chemistry ; Chemistry and Materials Science ; Chemistry/Food Science ; Chemokines ; Child ; Child, Preschool ; Children ; Dermatitis ; Dermatitis, Atopic - therapy ; Double-blind studies ; Eosinophil cationic protein ; Humans ; Immunoglobulin A ; Immunoglobulin E ; Inflammation ; Lactobacillus sakei ; Lymphocytes T ; Microbiology ; Nutrition ; Oral administration ; Placebos ; Probiotics ; Probiotics - therapeutic use ; Protein Science ; Skin ; Skin diseases ; Thymus</subject><ispartof>Probiotics and antimicrobial proteins, 2021-04, Vol.13 (2), p.315-326</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2907-7c1ec7420c24b65bc970f00b820b15d0eeffa7c6265bcb0a27838cbd1141f0c33</citedby><cites>FETCH-LOGICAL-c2907-7c1ec7420c24b65bc970f00b820b15d0eeffa7c6265bcb0a27838cbd1141f0c33</cites><orcidid>0000-0002-8795-9075</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12602-020-09654-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12602-020-09654-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32949011$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rather, Irfan A.</creatorcontrib><creatorcontrib>Kim, Byung-Chun</creatorcontrib><creatorcontrib>Lew, Lee-Ching</creatorcontrib><creatorcontrib>Cha, Seong-Kwan</creatorcontrib><creatorcontrib>Lee, Jong Hwan</creatorcontrib><creatorcontrib>Nam, Gyeong-Jun</creatorcontrib><creatorcontrib>Majumder, Rajib</creatorcontrib><creatorcontrib>Lim, Jeongheui</creatorcontrib><creatorcontrib>Lim, Seul-Ki</creatorcontrib><creatorcontrib>Seo, Young-Joon</creatorcontrib><creatorcontrib>Park, Yong-Ha</creatorcontrib><title>Oral Administration of Live and Dead Cells of Lactobacillus sakei proBio65 Alleviated Atopic Dermatitis in Children and Adolescents: a Randomized, Double-Blind, and Placebo-Controlled Study</title><title>Probiotics and antimicrobial proteins</title><addtitle>Probiotics & Antimicro. Prot</addtitle><addtitle>Probiotics Antimicrob Proteins</addtitle><description>Several studies suggest that probiotics might be useful in the management of atopic dermatitis (AD). However, the efficacy and comparison between both the administration of viable and non-viable probiotics on alleviation of AD is not well studied. Therefore, the purpose of this study was to evaluate the effect of
L. sakei
proBio65 live and dead cells when administered (1 × 10
10
cells/day) for 12 weeks to children and adolescents (aged 3 to 18) with atopic dermatitis. In this randomized double-blind, placebo-controlled study, ninety patients were recruited and randomly allocated to either the
L. sakei
proBio65 live cells,
L. sakei
proBio65 dead cells, or placebo groups. Assessment of efficacy was based on the change in SCORing Atopic Dermatitis (SCORAD) score, Investigators Global Assessment (IGA) score, serum inflammatory markers such as the serum eosinophil (count), IgE, eosinophil cationic protein (ECP), CCL17 (thymus and activation-regulated chemokine [TARC]), and CCL27 (cutaneous T cell–attracting chemokine [CTACK]), and changes in skin condition (moisture and sebum) at baseline, week 6 and week 12. The SCORAD total score decreased in the live cells (
p =
0.0015) and dead cell group (
p =
0.0017) from the baseline after 12 weeks, whereas there were no significant changes in the placebo group when compared with baseline. The skin sebum content increased in both the live cell (
p <
0.0001) and the dead cell group (
p <
0.0001), suggesting potential improvements in skin barrier functions. Current data suggested a positive improvement in alleviation of AD symptoms upon oral administration of
L. sakei
proBio65 in both viable and non-viable forms.</description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adolescents</subject><subject>Applied Microbiology</subject><subject>Atopic dermatitis</subject><subject>CCL17 protein</subject><subject>Chemistry</subject><subject>Chemistry and Materials Science</subject><subject>Chemistry/Food Science</subject><subject>Chemokines</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Dermatitis</subject><subject>Dermatitis, Atopic - therapy</subject><subject>Double-blind studies</subject><subject>Eosinophil cationic protein</subject><subject>Humans</subject><subject>Immunoglobulin A</subject><subject>Immunoglobulin E</subject><subject>Inflammation</subject><subject>Lactobacillus sakei</subject><subject>Lymphocytes T</subject><subject>Microbiology</subject><subject>Nutrition</subject><subject>Oral administration</subject><subject>Placebos</subject><subject>Probiotics</subject><subject>Probiotics - therapeutic use</subject><subject>Protein Science</subject><subject>Skin</subject><subject>Skin diseases</subject><subject>Thymus</subject><issn>1867-1306</issn><issn>1867-1314</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc1u1TAQhSMEoqXwAiyQJTYsCIydxE7YpWn5ka5UxM86cuwJuDj2xXYqlXfj3ep7bykSC1a2Z75zZqxTFE8pvKIA4nWkjAMrgUEJHW_qUtwrjmnLRUkrWt-_uwM_Kh7FeAnAecXgYXFUsa7ugNLj4vdFkJb0ejHOxBRkMt4RP5ONuUIinSZnKDUZ0Nq4L0uV_CSVsXaNJMofaMg2-FPjeUN6a_HKyISa9MlvjcrisGTLZCIxjgzfjdUB3d63195iVOhSfEMk-ZRrfjG_UL8kZ36dLJan1rj82sEfrVQ4-XLwLgWfx2jyOa36-nHxYJY24pPb86T4-vb8y_C-3Fy8-zD0m1KxDkQpFEUlagaK1RNvJtUJmAGmlsFEGw2I8yyF4mzXm0Ay0VatmjSlNZ1BVdVJ8eLgm__6c8WYxsXk3a2VDv0aR1bXdSXamtGMPv8HvfRrcHm7kTXQdcDbbmfIDpQKPsaA87gNZpHheqQw7sIdD-GOOdxxH-4osujZrfU6LajvJH_SzEB1AGJuuW8Y_s7-j-0NVgmwgw</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Rather, Irfan A.</creator><creator>Kim, Byung-Chun</creator><creator>Lew, Lee-Ching</creator><creator>Cha, Seong-Kwan</creator><creator>Lee, Jong Hwan</creator><creator>Nam, Gyeong-Jun</creator><creator>Majumder, Rajib</creator><creator>Lim, Jeongheui</creator><creator>Lim, Seul-Ki</creator><creator>Seo, Young-Joon</creator><creator>Park, Yong-Ha</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8795-9075</orcidid></search><sort><creationdate>20210401</creationdate><title>Oral Administration of Live and Dead Cells of Lactobacillus sakei proBio65 Alleviated Atopic Dermatitis in Children and Adolescents: a Randomized, Double-Blind, and Placebo-Controlled Study</title><author>Rather, Irfan A. ; Kim, Byung-Chun ; Lew, Lee-Ching ; Cha, Seong-Kwan ; Lee, Jong Hwan ; Nam, Gyeong-Jun ; Majumder, Rajib ; Lim, Jeongheui ; Lim, Seul-Ki ; Seo, Young-Joon ; Park, Yong-Ha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2907-7c1ec7420c24b65bc970f00b820b15d0eeffa7c6265bcb0a27838cbd1141f0c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adolescents</topic><topic>Applied Microbiology</topic><topic>Atopic dermatitis</topic><topic>CCL17 protein</topic><topic>Chemistry</topic><topic>Chemistry and Materials Science</topic><topic>Chemistry/Food Science</topic><topic>Chemokines</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Dermatitis</topic><topic>Dermatitis, Atopic - therapy</topic><topic>Double-blind studies</topic><topic>Eosinophil cationic protein</topic><topic>Humans</topic><topic>Immunoglobulin A</topic><topic>Immunoglobulin E</topic><topic>Inflammation</topic><topic>Lactobacillus sakei</topic><topic>Lymphocytes T</topic><topic>Microbiology</topic><topic>Nutrition</topic><topic>Oral administration</topic><topic>Placebos</topic><topic>Probiotics</topic><topic>Probiotics - therapeutic use</topic><topic>Protein Science</topic><topic>Skin</topic><topic>Skin diseases</topic><topic>Thymus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rather, Irfan A.</creatorcontrib><creatorcontrib>Kim, Byung-Chun</creatorcontrib><creatorcontrib>Lew, Lee-Ching</creatorcontrib><creatorcontrib>Cha, Seong-Kwan</creatorcontrib><creatorcontrib>Lee, Jong Hwan</creatorcontrib><creatorcontrib>Nam, Gyeong-Jun</creatorcontrib><creatorcontrib>Majumder, Rajib</creatorcontrib><creatorcontrib>Lim, Jeongheui</creatorcontrib><creatorcontrib>Lim, Seul-Ki</creatorcontrib><creatorcontrib>Seo, Young-Joon</creatorcontrib><creatorcontrib>Park, Yong-Ha</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Probiotics and antimicrobial proteins</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rather, Irfan A.</au><au>Kim, Byung-Chun</au><au>Lew, Lee-Ching</au><au>Cha, Seong-Kwan</au><au>Lee, Jong Hwan</au><au>Nam, Gyeong-Jun</au><au>Majumder, Rajib</au><au>Lim, Jeongheui</au><au>Lim, Seul-Ki</au><au>Seo, Young-Joon</au><au>Park, Yong-Ha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral Administration of Live and Dead Cells of Lactobacillus sakei proBio65 Alleviated Atopic Dermatitis in Children and Adolescents: a Randomized, Double-Blind, and Placebo-Controlled Study</atitle><jtitle>Probiotics and antimicrobial proteins</jtitle><stitle>Probiotics & Antimicro. Prot</stitle><addtitle>Probiotics Antimicrob Proteins</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>13</volume><issue>2</issue><spage>315</spage><epage>326</epage><pages>315-326</pages><issn>1867-1306</issn><eissn>1867-1314</eissn><abstract>Several studies suggest that probiotics might be useful in the management of atopic dermatitis (AD). However, the efficacy and comparison between both the administration of viable and non-viable probiotics on alleviation of AD is not well studied. Therefore, the purpose of this study was to evaluate the effect of
L. sakei
proBio65 live and dead cells when administered (1 × 10
10
cells/day) for 12 weeks to children and adolescents (aged 3 to 18) with atopic dermatitis. In this randomized double-blind, placebo-controlled study, ninety patients were recruited and randomly allocated to either the
L. sakei
proBio65 live cells,
L. sakei
proBio65 dead cells, or placebo groups. Assessment of efficacy was based on the change in SCORing Atopic Dermatitis (SCORAD) score, Investigators Global Assessment (IGA) score, serum inflammatory markers such as the serum eosinophil (count), IgE, eosinophil cationic protein (ECP), CCL17 (thymus and activation-regulated chemokine [TARC]), and CCL27 (cutaneous T cell–attracting chemokine [CTACK]), and changes in skin condition (moisture and sebum) at baseline, week 6 and week 12. The SCORAD total score decreased in the live cells (
p =
0.0015) and dead cell group (
p =
0.0017) from the baseline after 12 weeks, whereas there were no significant changes in the placebo group when compared with baseline. The skin sebum content increased in both the live cell (
p <
0.0001) and the dead cell group (
p <
0.0001), suggesting potential improvements in skin barrier functions. Current data suggested a positive improvement in alleviation of AD symptoms upon oral administration of
L. sakei
proBio65 in both viable and non-viable forms.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32949011</pmid><doi>10.1007/s12602-020-09654-7</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-8795-9075</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1867-1306 |
| ispartof | Probiotics and antimicrobial proteins, 2021-04, Vol.13 (2), p.315-326 |
| issn | 1867-1306 1867-1314 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2444378421 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Administration, Oral Adolescent Adolescents Applied Microbiology Atopic dermatitis CCL17 protein Chemistry Chemistry and Materials Science Chemistry/Food Science Chemokines Child Child, Preschool Children Dermatitis Dermatitis, Atopic - therapy Double-blind studies Eosinophil cationic protein Humans Immunoglobulin A Immunoglobulin E Inflammation Lactobacillus sakei Lymphocytes T Microbiology Nutrition Oral administration Placebos Probiotics Probiotics - therapeutic use Protein Science Skin Skin diseases Thymus |
| title | Oral Administration of Live and Dead Cells of Lactobacillus sakei proBio65 Alleviated Atopic Dermatitis in Children and Adolescents: a Randomized, Double-Blind, and Placebo-Controlled Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T22%3A30%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20Administration%20of%20Live%20and%20Dead%20Cells%20of%20Lactobacillus%20sakei%20proBio65%20Alleviated%20Atopic%20Dermatitis%20in%20Children%20and%20Adolescents:%20a%20Randomized,%20Double-Blind,%20and%20Placebo-Controlled%20Study&rft.jtitle=Probiotics%20and%20antimicrobial%20proteins&rft.au=Rather,%20Irfan%20A.&rft.date=2021-04-01&rft.volume=13&rft.issue=2&rft.spage=315&rft.epage=326&rft.pages=315-326&rft.issn=1867-1306&rft.eissn=1867-1314&rft_id=info:doi/10.1007/s12602-020-09654-7&rft_dat=%3Cproquest_cross%3E2444378421%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2509906893&rft_id=info:pmid/32949011&rfr_iscdi=true |